BB Biotech AG (XSWX:BION) Change In Receivables : CHF0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Change In Receivables?

BB Biotech AG's change in receivables for the quarter that ended in Dec. 2023 was CHF0.00 Mil. It means BB Biotech AG's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

BB Biotech AG's change in receivables for the fiscal year that ended in Dec. 2023 was CHF0.00 Mil. It means BB Biotech AG's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

BB Biotech AG's Accounts Receivable for the quarter that ended in Dec. 2023 was CHF0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BB Biotech AG's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BB Biotech AG's liquidation value for the three months ended in Dec. 2023 was CHF-313.44 Mil.

BB Biotech AG Change In Receivables Historical Data

The historical data trend for BB Biotech AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Change In Receivables Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

BB Biotech AG Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

BB Biotech AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

BB Biotech AG (XSWX:BION) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BB Biotech AG's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	111.17	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, BB Biotech AG's accounts receivable are only considered to be worth 75% of book value:

BB Biotech AG's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.501	-	313.937	+	0.75 * 0	+	0.5 * 0
=	-313.44

BB Biotech AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (XSWX:BION) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

Executives

Prof. Dr. Mads Krogsgaard Thomsen

Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines